Noteworthy - Pharmaceutical Executive



Africa: The Lost Continent No More

May 6, 2014

Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.

What's Real in Deals

May 1, 2014

Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.

2014 Brand of the Year

May 1, 2014

Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.

Diabetes Patients in China: Is Pharma Listening?

April 30, 2014

In China, diabetes patients are hungry for information about their condition, and are taking to social media to discuss it. But, asks Simon Li, is pharma paying attention?

Market Access for Specialty Products in Latin America

April 25, 2014

Andrea Sobrio and Dr. Sandra Schoenes examine the market access challenges and opportunities specifically for premium, specialty inpatient products in the LatAm region.

Mission Critical: Assessing Pharma's Drivers of Change

April 24, 2014

Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.

Sickle Cell Disease In Three Acts

April 22, 2014

Ben Comer reports on how new pipeline therapies, public research investments, and a renewed sociopolitical focus are working toward a happier outcome for sickle cell disease patients.

Regional Trends in Bioinnovation Investment

April 16, 2014

California's Bay Area and the Boston/Cambridge nexus continue to dominate bioinnovation in the US. Pharm Exec looks at the factors contributing to the strategic dominance of these regions.

European Clinical Trials: The Die Is Cast

April 15, 2014

Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.


Click here